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Rationale & Objective: Hyperuricemia has been
implicated in the development and progression of
chronic kidney disease. Verinurad is a novel,
potent, specific urate reabsorption inhibitor. We
evaluated the effects on albuminuria of intensive
urate-lowering therapy with verinurad combined
with the xanthine oxidase inhibitor febuxostat in
patients with hyperuricemia and type 2 diabetes
mellitus (T2DM).
Study Design: Phase 2, multicenter, prospective,
randomized, double-blind, parallel-group,
placebo-controlled trial.
Setting & Participants: Patients 18 years or
older with hyperuricemia, albuminuria, and T2DM.
Intervention: Patients randomly assigned 1:1 to
verinurad (9 mg) plus febuxostat (80 mg) or
matched placebo once daily for 24 weeks.
Outcomes: The primary end point was change in
urinary albumin-creatinine ratio (UACR) from
baseline after 12 weeks’ treatment. Secondary
end points included safety and tolerability and
effect on glomerular filtration.
Results: 60 patients were enrolled (n = 32, ver-
inurad and febuxostat; n = 28, placebo). UACRs
after treatment with verinurad plus febuxostat
were lower than after placebo at 1, 12, and 24
weeks: −38.6% (90% CI, −60.9%Editorial, p. 478
JKD Vol 77 | Iss 4 | April 2021to −3.6%), −39.4% (90% CI, −61.8% to −3.8%),
and −49.3% (90% CI, −68.2% to −19.0%),
respectively. Serum urate levels after treatment
with verinurad plus febuxostat were 59.6% and
63.7% lower than after placebo at 12 and 24
weeks, respectively. No clinically meaningful
changes were observed in estimated glomerular
filtration rate or serum creatinine or serum cys-
tatin C concentrations. Verinurad plus febuxostat
was well tolerated.
Limitations: Sample size and study duration
were insufficient to evaluate definitive effects of
verinurad plus febuxostat on UACR and glomer-
ular filtration. Generalizability was limited by
exclusion of patients with stages 4 and 5 chronic
kidney disease.
Conclusions: Verinurad plus febuxostat
reduced albuminuria and lowered serum urate
concentrations in patients with T2DM, albu-
minuria, and hyperuricemia. Definitive assess-
ment of their combined impact on preservation
of kidney function awaits larger clinical
studies.
Funding: This study was supported by
AstraZeneca.
Trial Registration: Registered at Clinical-
Trials.gov with study number NCT03118739.Type 2 diabetes mellitus (T2DM) remains the leadingcause of kidney failure,1 with a global increase in
chronic kidney disease (CKD) deaths due to T2DM of
39.5% between 2005 and 2015.2 Despite advances in
clinical care, including increased use of renin-angiotensinsystem (RAS) inhibitors and implementation of evidence-
based guidelines, patients with T2DM continue to have
high residual risk for progression to CKD and cardiovas-
cular (CV) events, especially those with albuminuria.3
Therefore, lowering albuminuria in patients with T2DM
remains a major goal to prevent CKD progression and its
consequences,4 with albuminuria emerging as a biomarker
for CKD progression and a surrogate end point for longer
term kidney disease outcomes.5,6
Hyperuricemia, characterized by elevated serum urate
concentrations, is associated with the presence anddevelopment of CKD. It is also an independent predictor
for the development of moderately increased albuminuria,
with risk greatest for those with the highest serum urate
concentrations.7 Furthermore, evidence from clinical trials
suggests that lowering serum urate levels through xanthine
oxidase inhibition may slow kidney disease progression
and reduce major renal and CV events.8-10 Underpinning
these clinical observations are experimental animal models
that suggest hyperuricemia induces kidney injury through
multiple pathways, including oxidative stress, vascular
smooth muscle proliferation, endothelial dysfunction, and
RAS dysregulation.11-13
Intensive lowering of serum urate levels may improve
kidney protection above and beyond existing renal pro-
tection strategies by reducing albuminuria and risk for
CKD progression. Verinurad is a novel, highly potent,
specific urate transporter 1 (URAT1) inhibitor that reduces
serum urate levels in patients with gout.14,15 By combining
verinurad with febuxostat, a competitive xanthine oxidase
inhibitor commonly used to treat hyperuricemia in481
PLAIN-LANGUAGE SUMMARY
People with chronic kidney disease and type 2 diabetes
are at risk for deteriorating kidney function and pro-
gressive chronic kidney disease. Loss of albumin into
the urine is an early marker of kidney damage and is
associated with further deterioration. In this study, the
combination of verinurad and febuxostat, drugs that
reduce uric acid levels using different mechanisms, led
to greater reductions in the amount of albumin in the
urine and uric acid in the blood than did placebo. The
treatment was generally well tolerated, with nausea and
dizziness the most common adverse events seen after
verinurad and febuxostat treatment. Although verinurad
and febuxostat may help protect the kidneys against
further decline in people with chronic kidney disease
and type 2 diabetes, definitive assessment of their
impact on preservation of kidney function awaits larger
clinical studies.
Stack et alpatients with gout,16 an intensive urate-lowering effect
may be achieved, potentially leading to greater kidney
protection. Preliminary studies in healthy volunteers have
shown that the novel combination of verinurad plus
febuxostat provides greater reductions in serum urate
levels than either drug alone,17 with dose-dependent re-
ductions in serum urate levels of up to 80% in patients
with gout and little change in urinary urate levels from
baseline.18,19
We hypothesized that an intensive urate-lowering
strategy with a combination of verinurad plus febuxostat
would reduce serum urate concentrations and lead to
measurable benefits on kidney function. The aim of this
trial was to evaluate the impact of this combination on
albuminuria in hyperuricemic patients with T2DM, assess
any additional effects on kidney function, and examine the
safety profile of this novel combination.Methods
Study Design
This was a multicenter, prospective, randomized, double-
blind, parallel-group, placebo-controlled trial in hyper-
uricemic patients with T2DM and albuminuria receiving
standard-of-care treatment (ClinicalTrials.gov identifier
NCT03118739). The primary objective was to assess the
effect of verinurad plus febuxostat on albuminuria. Sec-
ondary objectives included evaluation of kidney function,
CV health, and assessment of metabolic effects. The trial
was designed and conducted in accordance with the ethical
principles originating in the Declaration of Helsinki and in
compliance with the International Council for Harmo-
nisation and Good Clinical Practice. Ethical review and482approval of the study protocol were provided by the
Advarra Institutional Review Board.
Patients were randomly assigned 1:1 to once-daily oral
verinurad (9 mg) and febuxostat (80 mg) or matched
placebo. Randomization codes were assigned by the
investigator sequentially using the AstraZeneca randomi-
zation system (AZRand). Patients received treatment for 24
weeks and were evaluated at multiple predefined time
points for changes in outcome parameters. Patients were
followed up for 4 weeks after treatment had ended to
assess the effects of treatment discontinuation.
Because previous studies have reported transient eleva-
tions in serum creatinine levels with URAT1 inhibitors,20,21
strict discontinuation criteria were applied in the event of
creatinine level elevations at any time during the study. This
included serum creatinine level elevation of 3.0 or more
times baseline, absolute serum creatinine value ≥ 4.0 mg/
dL, or estimated creatinine clearance (CLcr) < 25 mL/min.
Study Participants
Adults 18 years or older with T2DM, serum urate con-
centration ≥ 6.0 mg/dL, estimated glomerular filtration
rate (eGFR) ≥ 30 mL/min/1.73 m2, and urinary albumin-
creatinine ratio (UACR) of 30 to 3,500 mg/g were
eligible for participation. Patients were required to be
receiving a stable dose of an RAS inhibitor (unless con-
traindicated, not tolerated, unavailable, or considered un-
suitable by the investigator) for 1 month or longer before
randomization.
Key exclusion criteria were prior treatment with any
urate-lowering agents in the 6 months before randomi-
zation, uncontrolled hypertension (systolic blood pres-
sure > 180 mm Hg), history of gout requiring prophylaxis
with nonsteroidal anti-inflammatory drugs or colchicine,
diagnosis of heart failure (New York Heart Association
functional classification class IV), known hypersensitivity
to either study drug, a change in dosage of certain agents
that can lower serum urate levels by nonselective mecha-
nisms (losartan, guaifenesin, fenofibrate, or sodium/
glucose cotransporter 2 inhibitors) within 2 weeks of
randomization or expected dose titration after randomi-
zation, and pregnancy, lactation, or plans for pregnancy. A
full list can be found in Table S1.
Informed consent was required before study participa-
tion. Patients were permitted to withdraw or discontinue
from the study for any reason, including patient or
physician decision, patients being lost to follow-up, or
adverse events (AEs).
Outcomes
The primary end point was change from baseline in UACR
within the treatment and placebo arms at 12 weeks,
expressed as the ratio of the UACR values. UACR was
measured at baseline in both study arms and at successive
predefined time points during the study. For UACR
determination, 3 first-morning urine void samples wereAJKD Vol 77 | Iss 4 | April 2021
Stack et alcollected at each visit: 2 days before, 1 day before, and on
the day of the study visit.
Several secondary end points were evaluated. The
effects of treatment on kidney function were evaluated
from measurement of changes in eGFR, serum cystatin
C, and serum creatinine values, as were the effects on
serum urate levels. To investigate the potential effects of
treatment on CV health, markers of CV stress (high-
sensitivity troponin I) and inflammation (high-sensitivity
C-reactive protein) were measured and compared be-
tween arms. Additional analysis explored the impact of
treatment on other related biomarkers. Vascular function
was assessed by measuring flow-mediated dilatation us-
ing a noninvasive device (SmartCuff; Cordex Systems
LLC). The effects of treatment on kidney and heart
structure and function were also investigated using
magnetic resonance imaging. Plasma exposure of ver-
inurad plus febuxostat was assessed from plasma trough
concentrations measured approximately 24 hours
postdosing.
Safety and tolerability were assessed from reports of
AEs, physical examinations, and changes in vital signs and
laboratory parameters.
Statistical Analysis
A placebo-corrected reduction in UACR of 30%, corre-
sponding to a ratio of 0.7 (−0.357 on a natural logarithmic
scale) was considered to be a clinically meaningful target
for this patient population, and a standard deviation (SD)
for change in ln(UACR) of 0.8 was assumed based on
previous studies.22 It was determined that 27 patients per
arm with available UACR data at baseline and at 12 weeks
should ensure with 90% probability that the observed
placebo-controlled reduction does not differ from the true
unknown reduction with more than this clinically mean-
ingful effect under the assumed SD. It was therefore
planned to enroll 30 patients per treatment arm for 1:1
randomization to ensure the availability of 27 evaluable
patients per arm.
A mixed-effects model for repeated measures was used
to analyze both primary and secondary efficacy variables
for the full analysis set, following the intent-to-treat
principle. Measurements were taken at baseline; weeks 1,
2, 4, 12, and 24; and at follow-up for all primary and
secondary efficacy variables. In this analysis, ln(UACR) was
the outcome and change in ln(UACR) was the parameter
of interest. For the primary outcome, ln(UACR) was the
response variable with randomized treatment and visit as
fixed discrete factors and baseline ln(UACR) and patients
as random factors. Treatment-visit interactions were
included in the mixed-effects model. Geometric least
squares mean changes from baseline in ln(UACR) and 95%
CIs were calculated by treatment and by visit at the 0.05
significance level, and least squares mean differences be-
tween treatment arms were calculated with the same
mixed-effects model for repeated measures by visit butAJKD Vol 77 | Iss 4 | April 2021presented with 90% CI as prespecified due to the limited
sample size.
Standard descriptive statistics were calculated for other
variables associated with primary, secondary, and explor-
atory objectives. Safety data were also presented as stan-
dard descriptive statistics by treatment and visit, as well as
change from baseline.Results
Characteristics of Study Participants
In total, 60 patients were enrolled from 19 sites across the
United States from May 2017 until January 2018; a total of
32 were randomly assigned to the verinurad plus
febuxostat group, and 28, to the placebo group (Fig 1).
Baseline demographic and clinical characteristics were
generally balanced between the 2 study groups (Table 1);
mean age was 61.5 years, 70% were men, and 62% were
White. Mean baseline UACR was 459.1 ± 824.7 (SD) mg/
g in the verinurad plus febuxostat group and
411.6 ± 547.8 mg/g in the placebo group. Overall, 47%
of patients had a baseline eGFR < 60 mL/min/1.73 m2.
Mean eGFRs were 59.2 and 68.1 mL/min/1.73 m2 in the
verinurad plus febuxostat and placebo groups, respectively
(Table 2).
In the verinurad plus febuxostat group, 81% and 75%
of patients completed 12 and 24 weeks of treatment,
respectively. In the placebo group, 89% of patients
completed both 12 and 24 weeks of treatment.
Effect of Verinurad Plus Febuxostat Therapy on
UACR
The study met the primary objective with a reduction in
UACR from baseline at 12 weeks for verinurad plus
febuxostat versus placebo (Table 2; Fig 2). At week 12,
mean percentage change from baseline in UACR
was −48.7% (95% CI, −64.8% to −25.1%) for verinurad
plus febuxostat and −15.3% (95% CI, −43.2% to 26.4%)
for placebo. A difference between the 2 treatment arms
was apparent as early as 1 week after starting treatment
(mean percent change for verinurad plus febuxostat vs
placebo: −38.6% [90% CI, −60.9% to −3.6%]) and per-
sisted throughout the 24-week study period (Fig 2). At 12
weeks, the primary end point assessment, mean percentage
change in UACR for verinurad plus febuxostat versus
placebo, was −39.4% (90% CI, −61.8% to −3.8%).
Post hoc changes in UACR at 24 weeks showed similar
trends to those recorded at 12 weeks (Table 2; Figs 2 and
S1). Mean percent change from baseline in UACR
was −38.4% (95% CI, −58.1% to −9.5%) for verinurad
plus febuxostat and 21.4% (95% CI, −18.9% to 81.8%) for
placebo. A difference between verinurad plus febuxostat
versus placebo of −49.3% (90% CI, −68.2% to −19.0%)
was observed. The treatment effect with the verinurad plus
febuxostat combination was consistent with a true phar-
macologic effect, as shown by an increase from baseline in483
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Figure 1. Patient disposition. Abbreviation: AE, adverse event.
Stack et alUACR at 4 weeks after the end of treatment (mean change
in UACR from baseline at follow-up, 184.28 mg/g for
verinurad plus febuxostat and 71.94 mg/g for placebo).
Effect of Treatment on Serum Urate Levels and
Markers of Kidney Function
The reduction in serum urate levels from baseline was
notably greater with verinurad plus febuxostat compared
with placebo at both week 12 and week 24 (Table 2)
despite the sample collection scheme being optimized for
pharmacokinetic rather than serum urate assessment,
resulting in underestimation of the effect on serum urate
levels. Mean percentage changes from baseline
were −56.8% (95% CI, −63.9% to −48.4%) and −61.9%
(95% CI, −68.3% to −54.3%) for the verinurad plus
febuxostat combination and 6.9% (95% CI, −11.8% to
29.5%) and 4.7% (95% CI, −13.8% to 27.2%) for placebo
at each time point, respectively (Fig 3). Mean percentage
changes for verinurad plus febuxostat versus placebo at
weeks 12 and 24 were −59.6% (90% CI, −67.6%
to −49.6%) and −63.7% (90% CI, −71.0% to −54.5%),
respectively.
Verinurad plus febuxostat had no apparent effect on
eGFR versus placebo in patients at the end of treatment
(week 24; Table 2; Fig 4).
No pronounced differences between the verinurad
plus febuxostat and placebo arms were noted for serum
creatinine or cystatin C levels at weeks 12 and 24
(Table 2).484Additional Secondary Outcomes
No clinically meaningful changes were observed for any of
the other secondary outcomes. Of note, serum high-
sensitivity C-reactive protein and serum high-sensitivity
troponin I levels did not appear to differ notably from
baseline or between the 2 treatment groups at weeks 12 or
24 (Table 3). Baseline cardiac magnetic resonance imaging
findings indicated that patients had better cardiac structure
and function across a range of parameters than was ex-
pected, leaving limited scope for improvement in these
during the study period. No changes from baseline in
blood oxygenation level–dependent magnetic resonance
imaging measurements of renal oxygenation were detec-
ted. No clinically significant changes in blood pressure
from baseline occurred with verinurad plus febuxostat
treatment.
Plasma trough concentrations of verinurad and
febuxostat remained steady during the course of the study
and were similar to those reported in other studies.
Exploratory Outcomes
Flow-mediated vascular dilatation at baseline was compa-
rable between the verinurad plus febuxostat (mean of
60.4% ± 28.8%) and placebo (60.6% ± 30.9%) groups.
Mean changes from baseline at weeks 12 and 24 were not
notably different: verinurad and febuxostat, 0.8 (95%
CI, −10.6 to 12.2) and 0.5 (95% CI, −9.4 to 10.5),
respectively; and placebo, −5.9 (95% CI, −17.0 to 5.3)
and −5.5 (95% CI, −15.5 to 4.4), respectively.AJKD Vol 77 | Iss 4 | April 2021





(n = 28) All (N = 60)
Male sex 22 (69%) 20 (71%) 42 (70%)
Age at screening, y 62.0 ± 9.5 60.9 ± 12.2 61.5 ± 10.7
Age at randomization
<65 y 16 (50%) 17 (61%) 33 (55%)
≥65 y 16 (50%) 11 (39%) 27 (45%)
Race
White 22 (69%) 15 (54%) 37 (62%)
Black or African
American
6 (19%) 5 (18%) 11 (18%)
Asian 3 (9%) 4 (14%) 7 (12%)
Native Hawaiian or
other Pacific Islander
1 (3%) 0 (0%) 1 (2%)
Other 0 (0%) 4 (14%) 4 (7%)
Weight, kg 93.7 ± 20.2 96.8 ± 19.6 95.1 ± 19.8
BMI, kg/m2 32.0 ± 5.1 33.0 ± 4.7 32.4 ± 4.9
eGFR
<30 mL/min/1.73 m2 2 (6%) 1 (4%) 3 (5%)
30-<60 mL/min/
1.73 m2
16 (50%) 9 (32%) 25 (42%)
60-<90 mL/min/
1.73 m2
9 (28%) 12 (43%) 21 (35%)
≥90 mL/min/1.73 m2 5 (16%) 6 (21%) 11 (18%)
Prior concomitant
medications
Agents acting on the
renin-angiotensin
system
25 (78%) 25 (89%) 50 (83%)
ACE inhibitors 16 (50%) 11 (39%) 27 (45%)
Angiotensin II
antagonists
4 (13%) 11 (39%) 15 (25%)
Note: Full analysis set. Values expressed as mean ± standard deviation or number
(percent).
Abbreviations: ACE, angiotensin-converting enzyme; BMI, body mass index; eGFR,
estimated glomerular filtration rate.
Table 2. Effect of Treatment on UACR, Serum Urate, and







Baseline 459.1 ± 824.7 411.6 ± 547.8
Week 12 218.0 ± 280.7 385.3 ± 484.8
Week 24 293.6 ± 371.5 501.8 ± 734.6
Follow-up 487.5 ± 714.1 523.5 ± 597.8
Serum urate, mg/dL
Baseline 7.5 ± 1.6 7.0 ± 0.8
Week 12 4.1 ± 2.6 7.4 ± 1.4
Week 24 4.1 ± 3.1 7.3 ± 1.2
Follow-up 7.5 ± 1.7 7.0 ± 1.2
eGFR, mL/min/1.73 m2
Baseline 59.2 ± 25.3 68.1 ± 23.2
Week 12 57.7 ± 21.3 64.4 ± 25.7
Week 24 53.7 ± 19.5 67.4 ± 24.3
Follow-up 51.1 ± 16.6 68.0 ± 27.1
Serum creatinine, mg/dL
Baseline 1.40 ± 0.60 1.19 ± 0.36
Week 12 1.35 ± 0.40 1.28 ± 0.44
Week 24 1.43 ± 0.40 1.22 ± 0.41
Follow-up 1.47 ± 0.46 1.23 ± 0.47
Cystatin C, mg/L
Baseline 1.58 ± 0.53 1.31 ± 0.35
Week 12 1.66 ± 0.53 1.35 ± 0.42
Week 24 1.71 ± 0.54 1.37 ± 0.36
Follow-up 1.75 ± 0.58 1.46 ± 0.39
Note: Values expressed as mean ± standard deviation.




















Verinurad and febuxostat Placebo
Figure 2. Estimated mean ratio of urinary albumin-creatinine ra-
tio (UACR) with 95% CIs by treatment visit. Error bars are 95%
CIs. Mixed-effects model for repeated measures with changes
from baseline in ln(UACR) as the response variable; randomized
treatment, visit, interaction of treatment group and visit as fixed
effects; baseline ln(UACR) as a covariate; and participant as a
random effect. Least squares mean (LSM) change in ln(UACR)
from baseline and the 95% CI of ln(UACR) were exponentiated
to yield the least square estimated mean ratio of UACR.
Stack et alModest changes from baseline were observed in both
study arms at week 24 for the exploratory urinalysis variables
but these were not considered clinically relevant. The urinary
protein-creatinine ratio was numerically lower in the ver-
inurad plus febuxostat arm compared with placebo at weeks
12 and 24 (Table S2). Urinary urate concentrations were also
lower in the verinurad and febuxostat–treated group
compared with placebo during follow-up (Table S2). Simi-
larly, small changes occurred in both study arms at 24 weeks
in clinical chemistry biomarker levels and were not consid-
ered clinically relevant (Table S2).
Safety
Treatment with verinurad plus febuxostat was generally
well tolerated. Treatment-emergent AEs occurred in 63%
of verinurad and febuxostat-treated patients and 46% of
placebo-treated patients and were mostly mild to moderate
in intensity. Serious AEs were reported in 5 (16%) patients
treated with verinurad plus febuxostat and in 3 (11%)
treated with placebo. There was a higher incidence ofAJKD Vol 77 | Iss 4 | April 2021gastrointestinal and respiratory, thoracic, and mediastinal
disorders with verinurad plus febuxostat than placebo

















Verinurad and febuxostat Placebo
Figure 3. Estimated mean ratio of serum urate (sUA) with 95%
CIs by treatment visit. Mixed-effects model for repeated mea-
sures with changes from baseline in sUA level as the response
variable; randomized treatment, visit, interaction of treatment
group, visit, and baseline sUA level as fixed effects; and partici-
pant as a random effect. Least squares mean (LSM) change in
ln(sUA) from baseline and the 95% CI of ln(sUA) were exponen-
tiated to yield the least square estimated mean ratio of sUA.
Table 3. Effect of Treatment on Biomarkers and Parameters







Baseline 0.41 ± 0.37 0.36 ± 0.25
Week 12 0.68 ± 1.07 0.48 ± 0.58
Week 24 0.41 ± 0.40 0.50 ± 0.58
Follow-up 0.42 ± 0.37 1.54 ± 4.65
Serum hsTnT, ng/
mL
Baseline 0.016 ± 0.045 0.040 ± 0.152
Week 12 0.012 ± 0.013 0.011 ± 0.012
Week 24 0.019 ± 0.043 0.040 ± 0.102
Follow-up 0.009 ± 0.008 0.009 ± 0.009
Note: Values given as mean ± standard deviation.
Abbreviations: hsCRP, high-sensitivity C-reactive protein; hsTnT, high-sensitivity
troponin 1.
Stack et aldizziness, and nasopharyngitis were reported most
frequently by patients who received verinurad plus
febuxostat (Table 4).
Twelve patients in the verinurad plus febuxostat
group (38%) and 6 patients in the placebo group (21%)
discontinued treatment (study treatment or the study).
Reasons for discontinuation included transient changes
to CLcr, other AEs, and patient withdrawal from study.
Five patients (16%) in the verinurad plus febuxostat
group and 1 patient (4%) in the placebo group dis-
continued treatment due to a treatment-emergent AE,
including 4 from the verinurad plus febuxostat group
who discontinued because of CLcr (<25 mL/min). In
general, CLcr < 25 mL/min, which required treatment
discontinuation, was a result of regular daily fluctuation


















Verinurad and febuxostat Placebo
Figure 4. Estimated mean ratio of estimated glomerular filtration
rate (eGFR) with 95% CIs by treatment visit. Mixed-effects
model for repeated measures with changes from baseline in
eGFR as the response variable; randomized treatment, visit,
interaction of treatment group, visit, and baseline eGFR as fixed
effects; and participant as a random effect. Least squares mean
(LSM) change in ln(eGFR) from baseline and the 95% CI of
ln(eGFR) were exponentiated to yield the least square estimated
mean ratio of serum eGFR.
486more patients in the verinurad plus febuxostat group
had eGFR < 45 mL/min/1.73 m2 at baseline, which
may have contributed to the discrepancy in discontin-
uation rates across groups. One patient in the verinurad
plus febuxostat treatment group discontinued study
drug because of nausea and diarrhea. AEs related to
laboratory findings occurred in 2 patients in the ver-
inurad plus febuxostat group and were in samples
drawn pre-dose on dosing day 1; 1 AE was “acute
kidney injury” and the other was “creatinine renal
clearance decreased.” Because both were found before
treatment start, neither was considered related to ver-
inurad or febuxostat.
No treatment-related serious AEs occurred. Serious
cardiac AEs were reported in the placebo group only.
Serum creatinine level elevations greater than 1.5 times
baseline occurred in 2 patients in each treatment arm
but resolved by the next visit. No hepatotoxicity con-
cerns were identified. No deaths were reported.Discussion
This proof-of-concept study showed that treatment with
verinurad, 9 mg, plus febuxostat, 80 mg, once daily
reduced albuminuria in patients with T2DM andTable 4. Treatment-Emergent Adverse Events Occurring in 2 or






Diarrhea 4 (12.5%) 1 (3.6%)
Dizziness 3 (9.4%) 0 (0.0%)
Nasopharyngitis 2 (6.3%) 1 (3.6%)
Congestive heart
failure
0 (0.0%) 2 (7.1%)
Troponin I
increased
0 (0.0%) 2 (7.1%)
AJKD Vol 77 | Iss 4 | April 2021
Stack et alhyperuricemia receiving standard-of-care renoprotective
treatment and optimal antihypertensive therapy. This
intensive urate-lowering strategy led to a 39% reduction in
UACR versus placebo after 12 weeks of treatment. Re-
ductions in UACR versus placebo were observed as early as
week 1 and were seen throughout the 24-week treatment
period. The magnitude of reduction in albuminuria ach-
ieved with verinurad plus febuxostat suggests that this
novel therapeutic approach may confer additional reno-
protection for patients with T2DM and hyperuricemia
beyond existing strategies.
The combination of verinurad plus febuxostat was well
tolerated, consistent with findings from previous studies
of verinurad alone in healthy adult men23 and febuxostat
alone in patients with gout.24 A higher number of pa-
tients in the verinurad plus febuxostat group dis-
continued treatment compared with the placebo group.
The reasons for discontinuation of treatment were
several, including nausea and diarrhea, which are
commonly reported AEs with febuxostat.24 For 2
treatment-emergent AEs of acute kidney injury and
decreased CLcr in patients on the verinurad plus febuxo-
stat arm, samples were drawn before randomization and
first drug use on study day 1 and were not considered
related to the study drug. It could not be ascertained
whether other suspected treatment-related discontinua-
tions constituted a real or spurious treatment effect; this
will be assessed in future studies. Measurements of kidney
function were closely monitored during treatment given
the potential of URAT1 inhibitors to alter uric acid con-
centrations in the tubular lumen.14,25 No measurable
effect of verinurad plus febuxostat on serum creatinine or
cystatin C concentrations was found.
No effects of verinurad plus febuxostat on eGFR were
observed; however, the study was not powered to detect
changes in eGFR of the magnitude that could be expected
in a study of this limited duration. The verinurad and
febuxostat-treated group had lower eGFR than the
placebo-treated group at baseline; however, no notable
differences were found between groups in eGFR assess-
ments during follow-up. Recent clinical trials have found
that urate-lowering therapies such as allopurinol or
febuxostat slow the rate of decline in eGFR.8-10 However,
this has not been observed in all studies.26-29 Differences in
clinical trial designs, such as insufficient sample size, het-
erogeneity in study design, and short follow-up times,
may account for these discrepancies.30 Future studies will
be required to assess whether verinurad in combination
with an xanthine oxidase inhibitor is superior to placebo in
preventing or slowing eGFR decline.
Albuminuria is the earliest clinical signal of kidney
disease in diabetic nephropathy and strategies that reduce
albuminuria, such as RAS inhibition, are standard of
care.1,4,31,32 However, despite receiving maximal tolerated
doses of RAS inhibitors, many patients continue to remain
at considerable risk for decline in eGFR and progression to
kidney failure.33 Novel strategies to lower serum urateAJKD Vol 77 | Iss 4 | April 2021levelsmay confer additional benefits beyond RAS inhibition.
There are several biological mechanisms through which
hyperuricemia may induce early kidney injury, including
induction of a specific afferent arteriolar vasculopathy,
promotion of endothelial dysfunction through nitric oxide
inhibition, and activation of the RAS.11-13 Although our
exploratory analysis did not reveal improvements inmarkers
of endothelial function or inflammation, the addition of a
urate-lowering strategy may inhibit many of these path-
ways, thereby reducing albuminuria. The identification and
validation of clinical biomarkers to serve as surrogate end
points for important clinical outcomes in nephrology is of
considerable interest to clinicians. Changes in albuminuria
and measured GFR over time are candidate biomarkers that
continue to receive significant attention for use in clinical
trials in CKD.6 A recent scientific workshop concluded that
changes in albuminuria and GFR slope fulfilled the criteria
for surrogate end points in clinical studies in CKDgiven their
strong relationships with major clinical end points in CKD.6
Themarked reduction in albuminuria observed in this early-
phase study provides an important positive signal for kidney
protection based on a verinurad-led urate-lowering
strategy.
This study was not without limitations. The sample size
was small and participation was limited to patients who
had T2DM and albuminuria, thereby preventing extrapo-
lation to the wider CKD population. Sample size was based
on results of studies performed in similar populations.34,35
Because there are few reported studies in this patient
population, the SD used to calculate sample size may not
reflect the true SD in ln(UACR). In addition, patients with
stage 4 or 5 CKD were excluded because URAT1 inhibitors
require relatively preserved kidney function for optimal
effect. eGFR was used instead of measured GFR to deter-
mine eligibility for the study and in monitoring partici-
pants over time, with potential for imprecision in
measurement. Finally, the effects of verinurad or febuxo-
stat alone were not explored in this study.
In conclusion, an intensive urate-lowering strategy with
a combination of verinurad plus febuxostat may lead to a
reduction in albuminuria among patients with T2DM and
hyperuricemia receiving standard-of-care RAS inhibition.
The observed effects of this treatment were independent of
blood pressure. This novel approach might confer addi-
tional benefits to patients with T2DM beyond the use of
existing renoprotective strategies. A larger phase 2b clinical
trial (ClinicalTrials.gov identifier NCT03990363) is
ongoing to confirm these findings.Supplementary Material
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Figure S1: Mean percentage change from baseline in UACR at 12
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Table S1: Study inclusion and exclusion criteria.
Table S2: The effect of treatment on kidney and vascular function
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